



Universiteit
Leiden
The Netherlands

Allosteric modulation and ligand binding kinetics at the Kv11.1 channel

Yu, Z.

Citation

Yu, Z. (2015, October 20). *Allosteric modulation and ligand binding kinetics at the Kv11.1 channel*. Retrieved from <https://hdl.handle.net/1887/35951>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/35951>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/35951> holds various files of this Leiden University dissertation.

Author: Yu, Zhiyi

Title: Allosteric modulation and ligand binding kinetics at the Kv11.1 channel

Issue Date: 2015-10-20

Chapter 3

Allosteric modulators of the K_v11.1 (hERG) channel

Radioligand binding assays reveal allosteric characteristics of dofetilide analogues

Zhiyi Yu
Elisabeth Klaasse
Laura H. Heitman
Adriaan P. IJzerman

Adapted from Toxicol. Appl. Pharmacol. 2014, 274, 78-86.

Abstract

Drugs that block the cardiac $K_v11.1$ channel encoded by the human ether-à-go-go gene (hERG) have been associated with QT interval prolongation leading to proarrhythmia, and in some cases, sudden cardiac death. Because of special structural features of the $K_v11.1$ channel, it has become a promiscuous target that interacts with pharmaceuticals of widely varying chemical structures and a reason for concern in the pharmaceutical industry. The structural diversity suggests that multiple binding sites are available on the channel with possible allosteric interactions between them. In the present study, three reference compounds and nine compounds of a previously disclosed series were evaluated for their allosteric effects on the binding of [3H]astemizole and [3H]dofetilide to the $K_v11.1$ channel. LUF6200 was identified as an allosteric inhibitor in dissociation assays with both radioligands, yielding similar EC_{50} values in the low micromolar range. However, potassium ions increased the binding of the two radioligands in a concentration-dependent manner, and their EC_{50} values were not significantly different, indicating that potassium ions behaved as allosteric enhancers. Furthermore, addition of potassium ions resulted in a concentration-dependent leftward shift of the LUF6200 response curve, suggesting positive cooperativity and distinct allosteric sites for them. In conclusion, our investigations provide evidence for allosteric modulation of the $K_v11.1$ channel, which is discussed in the light of findings on other ion channels.

Introduction

The $K_v11.1$ channel, encoded by the hERG gene¹, is responsible for the rapid delayed rectifier K^+ current (I_{Kr}) that plays a critical role in the repolarization of cardiomyocytes during the cardiac action potential². It is made up of large intracellular N- and C-terminal domains^{3,4} and four identical α -subunits, each of which is formed by six α -helical transmembrane domains and a looping “pore region”^{5,6}. In humans, blockade of the $K_v11.1$ channel by drugs can cause excessive lengthening of the action potential, which is reflected by a QT interval prolongation in the electrocardiogram (ECG)^{7,8}. The excessive action potential prolongation may combine to produce and sustain Torsade de Pointes (TdP), which can be self-limiting or degenerate into ventricular fibrillation rapidly leading to death^{6,8}. Therefore, it has become a routine practice in the pharmaceutical industry to test compounds for their $K_v11.1$ liability during early preclinical safety assessments according to FDA guidelines⁹. In recent years, most attention has been paid to assess the affinity for the $K_v11.1$ channel of potential drug candidates in order to avoid and discard modest-to-high affinity compounds during the lead finding and optimization process¹⁰. However, allosteric modulation of the $K_v11.1$ channel as an alternative way of interaction has not been studied in any details until now.

With regard to G protein-coupled receptors (GPCRs), successful drugs that mediate their effects through the allosteric modulation of target activity have already reached the market, also in view of their potential greater selectivity, potency and/or safety profile when compared to orthosteric ligands^{11,12}. Radioligand binding assays, in particular kinetic radioligand dissociation assays, have been widely utilized to quantify the allosteric effects of GPCR ligands¹³. As for ion channels, allosteric modulators have been reported for ligand-gated ion channels in particular. For example, GW791343 might be applied to treat inflammatory disorders and pain due to its allosteric inhibition of the $P2X_7$ receptor^{14,15}. A negative allosteric modulator of the nicotinic acetylcholine receptor, UCI-30002, had been reported to have significant benefits as a strategy for treating nicotine addiction because of its high subtype-selectivity¹⁶. It has also become increasingly apparent that new potent and selective allosteric modulators of the GABA-A receptor and 5-HT₃ receptor may replace conventional antagonists and agonists for these targets^{17,18}. Allosteric modulation of voltage-gated ion channels such as several types of calcium, sodium and potassium channels and their possible clinical applications has been investigated as well, but to a lesser extent. As an example, a novel quinazolinone ligand (TTA-Q4) showed a positive allosteric interaction with the T-Type calcium channel since it enhanced radioligand binding, increased affinity in a saturable manner and slowed dissociation¹⁹.




Figure 1. Compounds evaluated in this study. Terfenadine is a high-affinity reference $K_v11.1$ blocker, fluvoxamine is a low-affinity reference $K_v11.1$ blocker, PD118057 is a reference $K_v11.1$ activator, and all the other LUF compounds are members of a previously disclosed compound series interacting with the $K_v11.1$ channel.

Radioligand binding assays as a means of studying the $K_v11.1$ channel have been developed over the years. Two radioligands, [3H]astemizole and [3H]dofetilide, have mostly been used^{20–22}. The purpose of the present study was to identify and investigate allosteric modulators of the $K_v11.1$ channel using these two radioligands. The anti-depressant fluvoxamine²³ and the channel opener PD118057^{24, 25} (**Figure 1**), reported to have binding sites different from conventional $K_v11.1$ blockers, were selected as representative reference compounds. We identified a number of dofetilide analogues (**Figure 1**) displaying allosteric modulation in a pilot experiment and these were further investigated as were the allosteric effects of potassium ions in the same binding assays. Our findings suggest potential applications for such allosteric modulators, which might provide novel solutions for drug cardiotoxicity due to blockade of the $K_v11.1$ channel.

Materials and methods

Chemicals and reagents

Astemizole, terfenadine, fluvoxamine and PD118057 were purchased from Sigma Aldrich (Zwijndrecht, The Netherlands). Dofetilide and all the LUF compounds were synthesized in our own laboratory, as published previously²⁶. [3H]

Astemizole (specific activity 78.9 Ci·mmol⁻¹) and [³H]dofetilide (specific activity 70.0 Ci·mmol⁻¹) were purchased from Perkin Elmer (Groningen, The Netherlands). Bovine serum albumin (BSA, fraction V) was purchased from Sigma (St. Louis, MO). G418 was obtained from Stratagene (Cedar Creek, USA). All the other chemicals were of analytical grade and obtained from standard commercial sources. HEK293 cells stably expressing the K_v11.1 channel (HEK293K_v11.1) were kindly provided by Dr. Eckhard Ficker (University of Cleveland, USA).

Cell culture

HEK293K_v11.1 cells were cultured in a humidified atmosphere at 37 °C and 7% CO₂ in DMEM, containing 10% fetal calf serum, 50 IU mL⁻¹ penicillin, 50 µg·mL⁻¹ streptomycin and 1.25 µg·mL⁻¹ G418 for selection. Cells were subcultured twice a week (1:8). Then, the cells were subcultured 1:10 and transferred to large 15-cm diameter plates for membrane preparation.

Membrane preparation

HEK293K_v11.1 cells were grown to 80-90% confluence and detached from the plates by scraping them into 5 mL of PBS. Then, the detached cells were collected and centrifuged at 250 g for 10 min. The cell pellets were pooled and resuspended in 50 mM ice-cold Tris-HCl buffer containing 2 mM MgCl₂, pH 7.4. An UltraTurrax (Heidolph Instruments, Schwabach, Germany) was used to homogenize the cell suspension. Membranes and the cytosolic fraction were separated by centrifugation at 100,000 g in an Optima LE-80K ultracentrifuge (Beckman Coulter, Fullerton, CA) at 4 °C for 20 min. The pellets were resuspended in the Tris-HCl buffer, and the homogenization and centrifugation steps were repeated. The resulting pellets were resuspended in ice-cold incubation buffer (10 mM HEPES, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl₂, 1 mM EGTA, 10 mM glucose, 0.1% BSA, pH 7.4) using the UltraTurrax. Aliquots (125 or 250 µL) were stored at -80 °C. The protein concentration of the membranes was measured using the BCA method²⁷.

Kinetic radioligand association and dissociation assays

The incubation temperature and protein concentration were optimized for the kinetic studies. Three different temperatures (4, 15 and 25 °C) and five protein amounts (10, 15, 20, 30 and 50 µg) were investigated at the beginning of our research program. The optimal conditions for [³H]astemizole kinetic studies proved to be using 30 µg of membrane protein at an incubation temperature of 15 °C. The

association experiments of [^3H]astemizole were performed by incubating membrane aliquots containing 30 μg protein in a total volume of 100 μL incubation buffer at 15 $^{\circ}\text{C}$ for 90 min with 2 nM [^3H]astemizole. The amounts of radioligand bound to the receptor were measured at various time intervals during the incubation. The dissociation experiments were conducted by preincubating membrane aliquots containing 30 μg protein in a total volume of 100 μL incubation buffer at 15 $^{\circ}\text{C}$ for 90 min with 2 nM [^3H]astemizole. After preincubation, dissociation was initiated by addition of 10 μM astemizole for a total period of 60 min. The amounts of [^3H]astemizole still bound to the receptor were also measured at various time intervals. Separation of bound from free radioligand was performed by rapid filtration through Whatman GF/B filters using a Brandel harvester. Filters were subsequently washed six times with 2 mL ice-cold wash buffer (25 mM Tris-HCl, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl_2 , 0.05 mM CaCl_2 , 0.05% BSA, pH 7.4). Filter-bound radioactivity was determined by scintillation spectrometry using a liquid Scintillation Analyzer (Tri-Carb 2900TR) after addition of 3.5 mL Packard Emulsifier Safe and 2 h extraction.

For the kinetic studies of [^3H]dofetilide binding we used 20 μg of membrane protein at an incubation temperature of 25 $^{\circ}\text{C}$ with 5 nM [^3H]dofetilide. The association experiments were performed for 120 min, whereas the dissociation assays were induced by 10 μM dofetilide after a total period of 120 min preincubation and followed for another 60 min. Incubations were terminated, and samples were obtained and analyzed as described for [^3H]astemizole.

Kinetic radioligand dissociation assays-allosteric modulation

Single point dissociation assays

Dissociation experiments were mainly performed as described in the above paragraph. After preincubation, dissociation was initiated by addition of 10 μM astemizole or dofetilide in the absence (control) or presence of 10 μM of other ligands. After 10 min of dissociation, samples were separated by rapid filtration through a 96-well GF/B filter plate using a Perkin Elmer Filtermate-harvester (Perkin Elmer, Groningen, The Netherlands). Filters were subsequently washed twelve times with ice-cold wash buffer. The filter-bound radioactivity was determined by scintillation spectrometry using the 1450 Microbeta Wallac Trilux scintillation counter (Perkin Elmer) after addition of 37.5 μL Microscint and 2 h extraction. The binding of [^3H]astemizole or [^3H]dofetilide in the control was set as 100%.

Dissociation assays

After preincubation, dissociation was initiated by addition of 10 μ M astemizole or dofetilide in the absence (control) or presence of 10 μ M of possible allosteric modulators for a total period of 60 min. The amounts of radioligand still bound to the receptor were measured at various time intervals. Incubations were terminated, and samples were obtained as described in “*Single point dissociation assays*”.

Concentration dependency of allosteric modulators

In this setup the dissociation assay of [3 H]dofetilide was performed at 15 °C and the preincubation time to achieve radioligand association was 180 min; the dissociation assay for [3 H]astemizole was the same as described in “*Kinetic radioligand association and dissociation assays*”. After preincubation, dissociation was initiated by addition of 10 μ M astemizole or dofetilide in the absence (control) or presence of different concentrations of allosteric modulators. Incubations were terminated after 10 min of dissociation, and samples were obtained as described in “*Single point dissociation assays*”.

Equilibrium radioligand binding assays

The [3 H]astemizole and [3 H]dofetilide equilibrium binding assays for the K_v 11.1 channel were performed as described before^{20-22, 28} with minor modifications. In short, membrane aliquots containing 30 μ g protein for [3 H]astemizole or 20 μ g protein for [3 H]dofetilide were incubated in a total volume of 100 μ l incubation buffer at 25 °C for 60 min. Binding experiments were performed using a series of concentrations of potassium ions in the presence of 2 nM [3 H]astemizole or 5 nM [3 H]dofetilide. Nonspecific binding was determined in the presence of 10 μ M astemizole and represented approximately 15% of the total binding. [3 H]astemizole and [3 H]dofetilide did not show specific binding to membranes prepared from HEK293 cells lacking the expressed K_v 11.1 channel. The binding of [3 H]astemizole and [3 H]dofetilide in the presence of 100 mM KCl was set at 100% in all experiments, whereas nonspecific binding was set at 0%. Incubations were terminated by dilution with ice-cold wash buffer, and samples were obtained as described in “*Kinetic radioligand association and dissociation assays*”.

Cooperativity between different allosteric modulators

The dissociation assay of [3 H]dofetilide in the presence of different concentrations of KCl (2, 5, 10 and 60 mM) was performed as described in “*Concentra-*

tion dependency of allosteric modulators". After preincubation, dissociation was initiated by addition of 10 μM dofetilide in the absence (control) or presence of different concentrations of LUF6200. Incubations were terminated after 6 min of dissociation, and samples were obtained as described in "Single point dissociation assays".

Data analysis

All data of radioligand binding assays were analyzed with Prism v. 5.0 (Graph-Pad, San Diego, CA, USA). EC_{50} values for potassium ions were directly obtained from the non-linear regression concentration-effect curves. Dissociation rate constants, k_{off} , were obtained by computer analysis of the exponential decay of [^3H]astemizole or [^3H]dofetilide bound to the receptor. Association rate constants, k_{on} , were calculated according to the equation $k_{\text{on}} = (k_{\text{obs}} - k_{\text{off}})/[\text{L}^*]$, where the k_{obs} was obtained by computer analysis of the exponential association of [^3H]astemizole or [^3H]dofetilide bound to the receptor and $[\text{L}^*]$ was the amount of radioligand used for the association experiments. EC_{50} values from the dissociation experiments were calculated by non-linear regression analysis of concentration-effect curves of dissociation in the presence of different concentrations of unlabeled ligands. The differences of binding parameters between compounds and control were analyzed by an unpaired student t test. Significance was determined as $P < 0.05$. All values obtained are means of at least three independent experiments performed in duplicate.

Results

Optimization of assay conditions for [^3H]astemizole and [^3H]dofetilide kinetic study

Assay conditions were optimized according to a general radioligand binding protocol in our laboratory²⁹. Firstly, displacement assays for [^3H]astemizole and [^3H]dofetilide were performed at five different amounts of HEK293K_v11.1 membranes (10, 15, 20, 30 and 50 μg). A suitable window of specific [^3H]astemizole binding was obtained using 30 μg of membrane protein, whereas 20 μg of protein was required for [^3H]dofetilide binding to achieve a similar window. These membrane protein concentrations were also selected for the further kinetic study of two radioligands. Then, since it has been reported that compounds like AICAR or phenformine can also inhibit the K_v11.1 currents via activating AMP-dependent protein kinase³⁰, the binding of [^3H]astemizole and [^3H]dofetilide at membranes

prepared from HEK293 cells lacking the expressed $K_v11.1$ channel were determined. Neither of the two radioligands showed any specific binding here, indicating the direct binding of astemizole and dofetilide to the $K_v11.1$ channel. Subsequently, the association and dissociation of [3H]astemizole and [3H]dofetilide were determined at three different temperatures (4, 15 and 25 °C). The optimal incubation temperature was found to be 15 °C for [3H]astemizole and 25 °C for [3H]dofetilide concerning the appropriate on- and off-rates and the practical convenience of the experiments. Nevertheless, these findings were not applied too stringently as concentration-dependent effects of allosteric modulators of [3H]astemizole and [3H]dofetilide binding to the $K_v11.1$ channel were later conducted at 15 °C and concentration-effect curves for K^+ ions were recorded at 25 °C in order to obtain comparable results between the two radioligand binding assays.

Association and dissociation of [3H]astemizole from the HEK-293 $K_v11.1$ membranes

Because association and dissociation of [3H]astemizole from the HEK293 $K_v11.1$ membranes were both very fast at 25 °C, the kinetic study of [3H]astemizole binding was performed at 15 °C using 30 μ g HEK293 $K_v11.1$ membrane protein. The data were best described by non-linear regression using a mono-exponential model. As is shown in **Figure 2A** and **Table 1**, the binding equilibrium was reached within 90 min with a k_{on} value of $0.068 \pm 0.010 \text{ nM}^{-1} \cdot \text{min}^{-1}$. The dissociation rate and half-life time of [3H]astemizole were $0.055 \pm 0.010 \text{ min}^{-1}$ and $11 \pm 1.4 \text{ min}$, respectively (**Figure 2B** and **Table 1**). The dissociation of [3H]astemizole at 10 min was almost half of the total binding, so the 10-min dissociation time was selected for assessing the allosteric effects of compounds on the $K_v11.1$ channel in the follow-up experiments.




Figure 2. Association and dissociation curves of [3H]astemizole binding to the $K_v11.1$ channel. (**A**: Association curve; **B**: Dissociation curve) Dissociation was started by addition of 10 μ M astemizole after 90 min preincubation. Experiments were performed at 15

°C using 30 µg of HEK293K_v11.1 membrane protein.

Table 1. The association rate (k_{on}), dissociation rate (k_{off}) and the kinetically derived K_d of [³H]astemizole and [³H]dofetilide binding to the K_v11.1 channel.

	k_{on} (nM ⁻¹ ·min ⁻¹)	k_{off} (min ⁻¹)	K_d (nM)
Astemizole^a	0.068 ± 0.010	0.055 ± 0.010	0.85 ± 0.045
Dofetilide^b	0.032 ± 0.0026	0.20 ± 0.026	6.4 ± 1.3

Values are means (± S.E.M.) of at least three independent assays performed in duplicate.

^aThe association and dissociation assays of [³H]astemizole were performed at 15 °C.

^bThe association and dissociation assays of [³H]dofetilide were conducted at 25 °C.

Association and dissociation of [³H]dofetilide from the HEK-293K_v11.1 membranes

As is depicted in **Figure 3**, the association of [³H]dofetilide reached equilibrium at around 30 min, and it completely dissociated from the K_v11.1 channel within 60 min after addition of 10 µM dofetilide. By analyzing association and dissociation curves using a mono-exponential model, the k_{on} , k_{off} and $t_{1/2}$ values were 0.032 ± 0.0026 nM⁻¹·min⁻¹ and 0.20 ± 0.026 min⁻¹, respectively (**Table 1**). Similar to [³H]astemizole binding assay, a 10-min dissociation time point was chosen for the further study of allosteric modulators of the K_v11.1 channel.




Figure 3. Association and dissociation curves of [³H]dofetilide binding to the K_v11.1 channel. (A: Association curve; B: Dissociation curve) Dissociation was started by addition of 10 µM dofetilide after 120 min preincubation. Experiments were performed at 25 °C using 20 µg of HEK293K_v11.1 membrane protein.

Screening for allosteric modulators of [³H]astemizole and [³H]dofetilide binding

Table 2. The specific binding of [³H]astemizole and [³H]dofetilide to the K_v11.1 channel after 10 min of dissociation in the absence (B_{control}) or presence of 10 μM unlabelled ligands (B).

Compound	%B/B _{control} of [³ H]astemizole	%B/B _{control} of [³ H]dofetilide
Control	100 ± 0	100 ± 0
Terfenadine	98 ± 1	93 ± 7
Fluvoxamine	129 ± 13 *	95 ± 12
PD118057	133 ± 14 *	109 ± 2 *
LUF6145	109 ± 5	93 ± 2
LUF6171	102 ± 6	104 ± 3
LUF6173	97 ± 8	71 ± 5 *
LUF6200	39 ± 4 ***	50 ± 1 ***
LUF6202	70 ± 2 ***	62 ± 4 *
LUF6206	86 ± 2 ***	70 ± 7 *
LUF6208	36 ± 6 ***	47 ± 5 **
LUF6209	39 ± 2 ***	43 ± 8 *
LUF6217	53 ± 4 ***	54 ± 5 *

Values are means (± S.E.M.) of three independent assays performed in duplicate. (* P < 0.05; ** P < 0.01; *** P < 0.001 versus control)

We screened three reference ligands and an in-house library of K_v11.1 blockers (LUF compounds) to identify their allosteric effects on [³H]astemizole binding to the K_v11.1 channel using a single point dissociation assay. This protocol resulted in several compounds that potentially increased (allosteric enhancers) and decreased (allosteric enhancers) the dissociation of the radioligand. All the data are listed in **Table 2** and shown in **Figure 4**. Fluvoxamine and PD118057 appeared to increase the specific binding of [³H]astemizole by 29 and 33% above control after 10 min, suggesting that they might behave as allosteric enhancers of [³H]astemizole binding. On the contrary, some of the compounds synthesized in our laboratory including LUF6200, LUF6208, LUF6209 and LUF6217 substantially reduced the binding of [³H]astemizole, supporting their role as allosteric inhibitors by accelerating the dissociation of the radioligand. Among them, LUF6200, 6208 and LUF6209 were the most potent allosteric inhibitors with only 39 ± 4, 36 ± 6 and 39 ± 2% specific binding left compared with 100% for the control. In ad-

dition, LUF6202 and LUF6206 also displayed significant allosteric inhibition effects, but to a lesser extent. Other compounds (terfenadine, LUF6145, LUF6171 and LUF6173) had no significant allosteric modulatory effects in this experiment.




Figure 4. Bar graphs of the percentage specific binding of [³H]astemizole to the K_v11.1 channel after 10 min of dissociation induced by 10 μM astemizole in the absence (control) or presence of 10 μM of different compounds. The specific binding of [³H]astemizole in the absence of compounds was set as 100%. Experiments were performed at 15 °C using 30 μg HEK293K_v11.1 membrane protein.

The effects of the same compounds in the single point dissociation experiments of [³H]dofetilide binding to the K_v11.1 channel are shown in **Figure 5** and **Table 2**. The results obtained from this assay were almost the same as those derived from the [³H]astemizole binding assay. The only two exceptions were that fluvoxamine exerted no allosteric enhancement here and that LUF6173 now showed significant allosteric inhibition of [³H]dofetilide binding.




Figure 5. Bar graphs of the percentage specific binding of [³H]dofetilide to the K_v11.1 channel after 10 min of dissociation induced by 10 μM dofetilide in the absence (control) or presence of 10 μM of different compounds. The specific binding of [³H]dofetilide in the absence of compounds was set as 100%. Experiments were performed at 25 °C using 20 μg HEK293K_v11.1 membrane protein.

Subsequently, fluvoxamine, PD118057 and one potent representative allosteric inhibitor (LUF6200) were selected for the further experiments to validate their allosteric modulation effects.

Dissociation of [3 H]astemizole from the $K_v11.1$ channel: effects of fluvoxamine, PD118057 and LUF6200

The dissociation of [3 H]astemizole from the $K_v11.1$ channel was induced by 10 μ M astemizole in the absence (control) or presence of 10 μ M of fluvoxamine, PD118057 or LUF6200 during a 60-min time course at 15 $^{\circ}$ C. The results are depicted in **Figure 6**. The dissociation rates of [3 H]astemizole in the presence of fluvoxamine and PD118057 were $0.040 \pm 0.0091 \text{ min}^{-1}$ and $0.055 \pm 0.0053 \text{ min}^{-1}$, respectively, which were not significantly different from the control ($k_{\text{off}} = 0.055 \pm 0.010 \text{ min}^{-1}$). Moreover, the three curves in the absence or presence of fluvoxamine and PD118057 practically overlapped with each other. Thus, in this more detailed experiment, we verified that fluvoxamine and PD118057 did not allosterically enhance [3 H]astemizole binding at a concentration of 10 μ M. Interestingly, LUF6200 increased the dissociation rate of radioligand binding notably to a k_{off} value of $0.21 \pm 0.011 \text{ min}^{-1}$ ($P = 0.0005$), which corresponded to a 3.7-fold increase in the dissociation rate found for [3 H]astemizole alone.




Figure 6. Dissociation curves of [3 H]astemizole induced by 10 μ M astemizole in the absence (control) or presence of 10 μ M fluvoxamine, PD118057 and LUF6200. Experiments were performed at 15 $^{\circ}$ C using 30 μ g HEK293 $K_v11.1$ membrane protein.

Dissociation of [3 H]dofetilide from the $K_v11.1$ channel: effects of PD118057 and LUF6200

Since fluvoxamine was found to have no allosteric capacity in both the [3 H]astemizole and [3 H]dofetilide binding assays described above, only PD118057 and

LUF6200 were tested for their allosteric effects on [3 H]dofetilide binding to the $K_v11.1$ channel (**Figure 7**). The results demonstrated that LUF6200 accelerated the dissociation rate of [3 H]dofetilide from $0.20 \pm 0.026 \text{ min}^{-1}$ to $1.5 \pm 0.17 \text{ min}^{-1}$ ($P = 0.0016$), while the k_{off} of [3 H]dofetilide in the presence of $10 \mu\text{M}$ PD118057 was $0.20 \pm 0.015 \text{ min}^{-1}$, displaying no enhancement effects on the binding of [3 H]dofetilide. This further proved that LUF6200 was an allosteric inhibitor but that PD118057 was not an allosteric enhancer of the binding of $K_v11.1$ radioligands.




Figure 7. Dissociation curves of [3 H]dofetilide by $10 \mu\text{M}$ dofetilide in the absence (control) or presence of $10 \mu\text{M}$ PD118057 and LUF6200. Experiments were performed at 25°C using $20 \mu\text{g}$ HEK293 $K_v11.1$ membrane protein.

Concentration dependence of allosteric effects of LUF6200 on [3 H]astemizole and [3 H]dofetilide binding




Figure 8. Concentration dependence curves of LUF6200 for accelerating the [3 H]astemizole or [3 H]dofetilide dissociation from the $K_v11.1$ channel. Membranes were first pre-equilibrated with [3 H]astemizole or [3 H]dofetilide, then the dissociation was induced by $10 \mu\text{M}$ astemizole or dofetilide in the absence (control) or presence of different concentrations of LUF6200 and the reaction was terminated after 10 min. The results are expressed as the ratio of the specific binding of [3 H]astemizole or [3 H]dofetilide in the

presence of 10 μM astemizole or dofetilide plus various concentrations of LUF6200 (B) over that in the presence of 10 μM astemizole or dofetilide alone (B_{control}). Experiments were performed at 15 $^{\circ}\text{C}$ using 30 μg HEK293K_v11.1 membrane protein for [^3H]astemizole and 20 μg membrane protein for [^3H]dofetilide binding.

The influence of increasing concentrations of LUF6200 on the dissociation of [^3H]astemizole and [^3H]dofetilide induced by 10 μM astemizole or dofetilide is shown in **Figure 8**. After 10 min of dissociation, the process was terminated by washing and rapid filtration. LUF6200 accelerated the dissociation of [^3H]astemizole and [^3H]dofetilide in a concentration-dependent manner with similar, not statistically significantly different, EC_{50} values of 4.9 ± 0.52 and 3.4 ± 0.97 μM , respectively ($P = 0.45$).

Concentration dependent effects of potassium ions on [^3H]astemizole and [^3H]dofetilide binding

To assess the influence of increasing concentrations of potassium ions on the binding of [^3H]astemizole and [^3H]dofetilide, we determined the specific binding of [^3H]astemizole and [^3H]dofetilide at different concentrations of KCl after 60 min preincubation at 25 $^{\circ}\text{C}$. The results are shown in **Figure 9**. The binding of both [^3H]astemizole and [^3H]dofetilide were elevated with increasing concentrations of potassium ions and reached a plateau as of a concentration of 30 mM. The mean EC_{50} values in the two different radioligand binding assays were 7.2 ± 0.60 mM and 8.1 ± 0.47 mM for [^3H]astemizole and [^3H]dofetilide, respectively, which were not significantly different ($P = 0.30$). It is also worth noting that when no potassium ions were added to incubation mixture, the specific binding of [^3H]astemizole and [^3H]dofetilide was negligible (data not shown).




Figure 9. Dose-response curves of the specific binding of [^3H]astemizole and [^3H]dofetilide at different concentrations of potassium ions. Experiments were performed at 25 $^{\circ}\text{C}$

using 30 μg HEK293K_v11.1 membrane protein for [³H]astemizole binding and 20 μg membrane protein for [³H]dofetilide binding.

Effects of potassium ions on the acceleration of the [³H]dofetilide dissociation rate induced by LUF6200

In order to investigate whether the two modulators described above acted at different sites to produce these effects, the concentration-dependent effect of LUF6200 on [³H]dofetilide dissociation was studied in the presence of four different concentrations of KCl (**Figure 10**). The data obtained are represented in two formats. **Figure 10A** shows that addition of potassium ions decreased the dissociation, whereas LUF6200 dose-dependently enhanced that dissociation. **Figure 10B** demonstrates that addition of potassium ions resulted in a concentration-dependent leftward shift of the LUF6200 concentration-effect curve. The EC₅₀ values of LUF6200 in the presence of 2, 5, 10 and 60 mM potassium ions were 11 ± 1.7 , 6.4 ± 0.74 , 4.7 ± 0.53 and 3.5 ± 0.12 μM , respectively. This indicates that LUF6200 and potassium ions act at distinct allosteric sites on the K_v11.1 channel, and that potassium ions enhanced the allosteric effect of LUF6200.




Figure 10. Concentration-effect curves of LUF6200 for accelerating the [³H]dofetilide dissociation from the K_v11.1 at 2, 5, 10 and 60 mM potassium ions before (**A**) and after normalization (**B**), and the positive cooperativity effect of potassium ions on LUF6200 in enhancing [³H]dofetilide dissociation (**C**). Membranes were first pre-equilibrated with [³H]dofetilide at different concentrations of potassium ions, then the dissociation was in-

duced by 10 μM dofetilide in the absence (control) or presence of different concentrations of LUF6200 and the reaction was terminated after 6 min. The results in **B** are expressed as the ratio of the specific binding of [^3H]dofetilide in the presence of 10 μM dofetilide plus various concentrations of LUF6200 (B) over that in the presence of 10 μM dofetilide alone (B_{control}). Experiments were performed at 15 $^{\circ}\text{C}$ using 20 μg HEK293K $_{\text{v}}$ 11.1 membrane protein. The experimental data of different concentrations of potassium ions affecting the modulating potency of LUF6200 are exhibited with standard error of the mean from three independent experiments (**C**).

Last, the cooperativity between LUF6200 and potassium ions was further analyzed according to a cooperativity model studied by us previously³¹, and the curve connecting all the data is displayed in **Figure 10C**. We discriminated three possible situations³¹, in which two compounds showed positive ($\delta > 1$), neutral ($\delta = 1$) or negative cooperativity ($\delta < 1$). In the present study, our data points complied with $\delta > 1$, thus further supporting a positive cooperativity between the binding of LUF6200 and potassium ions.

Discussion

In the present study, we evaluated the allosteric effects of a series of compounds with diverse chemical structures on the K $_{\text{v}}$ 11.1 channel using both [^3H]astemizole and [^3H]dofetilide binding assays, and also addressed the influence of potassium ions on the binding of two radioligands. To the best of our knowledge, this study is the first time to utilize radioligand binding assays for the characterization of allosteric modulators for the K $_{\text{v}}$ 11.1 channel. From these initial results, one potent allosteric inhibitor (LUF6200) was identified and several other compounds including LUF6208, LUF6209, LUF6217, LUF6202 and LUF6206 were also shown to possess allosteric inhibitory effects in two radioligand binding assays. Moreover, potassium ions increased the binding of [^3H]astemizole and [^3H]dofetilide to the K $_{\text{v}}$ 11.1 channel. Additionally, fluvoxamine and PD118057, known to have binding sites distinct from most other K $_{\text{v}}$ 11.1 blockers, exhibited no allosteric effects in this investigation.

A common binding site for a wide spectrum of K $_{\text{v}}$ 11.1 blockers, including astemizole and dofetilide, has been implied through different methods^{32, 33}. However, the amino acid residues involved in the interaction of these structurally diverse compounds may be different³². Therefore, in this study two different radioligands ([^3H]astemizole and [^3H]dofetilide) were adopted in order to study, validate and compare the behavior of putative allosteric modulators. Since an altered dissociation rate is unequivocally indicative of an allosteric interaction³⁴, [^3H]astemizole and [^3H]dofetilide dissociation assays were firstly developed and then performed

to reveal the allosteric effects of different ligands. The results in this paper show that both [^3H]astemizole and [^3H]dofetilide exhibit fast association rates and dissociate from the $\text{K}_{\text{v}}11.1$ channel after addition of an excess of unlabelled astemizole or dofetilide, indicative of the reversible binding of the two ligands. Additionally, both the association and dissociation curves of the two radioligands are better fitted with a single-site than a two-site model, which is different from the two binding sites model for [^3H]dofetilide reported by Duff et al.³⁵ However, the latter experiments were performed on intact cells instead of membrane preparations used in our study. The diffusion into and possible trapping of [^3H]dofetilide inside the intact cells might affect the association and dissociation of the radioligand significantly.

Subsequently, single time point dissociation assays were conducted to screen for allosteric modulators of the $\text{K}_{\text{v}}11.1$ channel. LUF6200 was selected as a representative allosteric inhibitor from the screening experiments due to its potent effects on both [^3H]astemizole and [^3H]dofetilide binding. Besides, terfenadine, which occupies the same binding site as astemizole and dofetilide³⁶, did not display allosteric effects in either of the two radioligand screening assays, suggesting the validity and accuracy of our methods. To further characterize the allosteric effects of LUF6200, a full radioligand dissociation assay was performed in the presence of this compound. LUF6200 caused a 3.7- and 7.5-fold increase in the dissociation rates of [^3H]astemizole and [^3H]dofetilide, respectively. This further supports the notion that LUF6200 is an allosteric inhibitor of conventional $\text{K}_{\text{v}}11.1$ blockers binding to the $\text{K}_{\text{v}}11.1$ channel. The EC_{50} values from the two different radioligand dissociation assays were almost the same and in the micromolar range, which suggests that astemizole and dofetilide occupy the same binding site on the $\text{K}_{\text{v}}11.1$ channel. In a previous study from our laboratory, LUF6200 displaced [^3H]astemizole binding from the $\text{K}_{\text{v}}11.1$ channel under equilibrium conditions with a very low K_{i} value of $1.2 \pm 0.6 \text{ nM}$ ²⁶. As is evident from **Figure 8**, there is little or negligible allosteric inhibition observed for LUF6200 at a concentration lower than $0.1 \mu\text{M}$. Taken together, we conclude that LUF6200 interacts with the $\text{K}_{\text{v}}11.1$ channel in a complicated fashion: it behaves as an orthosteric blocker at lower concentrations and as an allosteric inhibitor at higher concentrations.

Two major binding regions have been hypothesized for the $\text{K}_{\text{v}}11.1$ channel, one in the transmembrane region, the other extracellularly^{37, 38}. Most $\text{K}_{\text{v}}11.1$ blockers bind to the central transmembrane cavity of the channel, whereas agents described as facilitators, activators or enhancers of the $\text{K}_{\text{v}}11.1$ channel usually interact with a region facing away from the inner cavity³⁷. For instance, A-935142 has recently been stated to possess a binding site responsible for $\text{K}_{\text{v}}11.1$ current enhancement which is different from the pore binding site for traditional

K_v11.1 blockers³⁹. The binding sites of several peptide blockers like saxitoxin and BeKm-1 are located in the extracellular parts of the K_v11.1 channel^{40, 41} and some metal ions bind to different regions of the pore of the channel in comparison to most other K_v11.1 blockers^{42, 43}. Additionally, it has been reported that a few nontoxin K_v11.1 blockers are unlikely to fit within the inner cavity and must bind elsewhere^{23, 44}. Thus, multiple binding sites of these diverse compounds or ions at the K_v11.1 channel imply the plausible allosteric modulation between them. They might allosterically increase (allosteric inhibitors/negative allosteric modulators) or decrease (allosteric enhancers/positive allosteric modulators) the dissociation rates of typical K_v11.1 blockers from the channel. The current study does not allow determining the location of the putative binding site of LUF6200. Its nanomolar potency as a classical blocker suggests that it interacts with the central cavity; for its allosteric property a different binding site or different conformation of the channel may play a role, and further studies such as cross linker and western blotting experiments are required to elucidate the exact binding sites of this compound.

The results in this paper also show that fluvoxamine does not behave as an allosteric modulator when tested in a rigorous kinetic assay. However, it has been reported that the binding of fluvoxamine to the K_v11.1 channel did not involve amino acids such as Y652 and F656 that are crucial to the binding of other general K_v11.1 blockers^{45, 46}; hence, it was suggested that fluvoxamine probably binds to an extracellular site at the outer mouth of the channel²³. In addition, the activator PD118057 did not exert allosteric enhancement in both [³H]astemizole and [³H]dofetilide dissociation assays. PD118057 has been identified to bind to a hydrophobic binding pocket instead of the shared binding site for K_v11.1 blockers at the channel⁴⁷. The results obtained for these two compounds suggest that even though a compound binds to a distinct region of the K_v11.1 channel, its allosteric effects on the binding of other K_v11.1 blockers are still uncertain and need to be validated in more detailed experiments.

Since it has been reported that the extracellular potassium concentration affected the binding of [³H]dofetilide to neonatal mouse myocytes⁴⁸, we also studied the allosteric effects of potassium ions and found that these monovalent cations increase both [³H]astemizole and [³H]dofetilide binding in a concentration-dependent manner with very similar EC₅₀ values. In earlier studies on a variety of ion channels, it was reported that metal ion binding to the pore of an ion channel may affect the occupancy of the binding site for other ligands and thus decrease their binding^{42, 49}. This is in contrast to the observation in our study. Thus, we assume that K⁺ ions possibly function as an allosteric enhancer of K_v11.1 blockers by changing the conformation of their binding site rather than competitively oc-

cupying their binding site. Since two distinct allosteric sites on the human GnRH receptor³¹ and three different allosteric sites on the dopamine D₄ receptor⁵⁰ have been reported, we wondered whether LUF6200 and potassium ions exert their effect through two distinct allosteric sites on the K_v11.1 channel as well. Potassium ions both enhance the allosteric effect of LUF6200 and shift the LUF6200 dose–response curve to the left, supporting that the two modulators are indeed acting at different binding sites at the K_v11.1 channel. Furthermore, a curve described in **Figure 10C** indicated a positive cooperativity between LUF6200 and potassium ions. Taken together, we anticipate that there are at least two different sites of allosteric modulation for K_v11.1 blockers at the channel and that they interact with each other as well.

It is hypothesized that the ceiling effect of allosteric modulators of ligand-gated ion channels has important advantages over classic orthosterically acting compounds or open channel blockers, because it offers a much larger safety margin when it comes to drug administration and patient compliance⁵¹. A similar scenario may also be feasible for the K_v11.1 channel. For allosteric inhibitors one might argue that when non-cardiovascular drugs (e.g., astemizole) are combined with allosteric inhibitors of the K_v11.1 channel, their cardiac side effects might be diminished. On the other hand, when allosteric enhancers are administered together with antiarrhythmic drugs such as dofetilide whose desired target is the K_v11.1 channel, the therapeutic dose might be lowered, thereby possibly preventing adverse drug reactions such as TdP. Taken together, the discovery of allosteric modulators for the K_v11.1 channel might open new avenues for treating clinical conditions related to the K_v11.1 channel as well as potentially reducing K_v11.1 cardiotoxicity of other non-cardiovascular drugs by combination therapy.

In summary, the present study provides evidence for the allosteric effects of dofetilide analogues on the binding of K_v11.1 blockers to the K_v11.1 channel using both [³H]astemizole and [³H]dofetilide binding assays. LUF6200 emerges as an allosteric inhibitor with micromolar potency. Potassium ions allosterically enhance the binding of typical K_v11.1 blockers in concentrations that are physiologically relevant. Moreover, LUF6200 and potassium ions act at distinct allosteric sites on the K_v11.1 channel, and these binding sites show positive cooperativity. In addition, neither fluvoxamine nor PD118057 exhibit significant allosteric effects on the binding of two radioligands. This new information may be relevant for a further analysis of K_v11.1-related cardiotoxicity and provide novel solutions for proarrhythmic side effects induced by K_v11.1 blockers.

References

1. Keating, M. T.; Sanguinetti, M. C. Molecular and cellular mechanisms review of cardiac arrhythmias. *Cell* **2001**, *104*, 569-580.
2. Hoppe, U. C.; Marbán, E.; Johns, D. C. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, hERG and KCNE1. *Proc. Natl. Acad. Sci. U S A* **2001**, *98*, 5335-5340.
3. Schönherr, R.; Heinemann, S. H. Molecular determinants for activation and inactivation of hERG, a human inward rectifier potassium channel. *J. Physiol.* **1996**, *493*, 635-642.
4. Ng, C. A.; Hunter, M. J.; Perry, M. D.; Mobli, M.; Ke, Y.; Kuchel, P. W.; King, G. F.; Stock, D.; Vandenberg, J. I. The N-terminal tail of hERG contains an amphipathic α -helix that regulates channel deactivation. *PLoS One* **2011**, *6*, e16191.
5. Finlayson, K.; Witchel, H. J.; McCulloch, J.; Sharkey, J. Acquired QT interval prolongation and hERG: Implications for drug discovery and development. *Eur. J. Pharmacol.* **2004**, *500*, 129-142.
6. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. *Nat.* **2006**, *440*, 463-469.
7. Vandenberg, J. I.; Walker, B. D.; Campbell, T. J. hERG K⁺ channels: Friend and foe. *Trends Pharmacol. Sci.* **2001**, *22*, 240-246.
8. Hancox, J. C.; McPate, M. J.; El Harchi, A.; Zhang, Y. h. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. *Pharmacol. Ther.* **2008**, *119*, 118-132.
9. Sanguinetti, M. C.; Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. *Trends Pharmacol. Sci.* **2005**, *26*, 119-124.
10. Gintant, G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. *Pharmacol. Ther.* **2011**, *129*, 109-119.
11. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. *Annu. Rev. Pharmacol. Toxicol.* **2007**, *47*, 1-51.
12. IJzerman, A. P.; Wijngaarden, I. v.; Soudijn, W. Allosteric modulation of G-protein-coupled receptors. *Expert Opin. Ther. Pat.* **2001**, *11*, 1889-1904.
13. Christopoulos, A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. *Nat. Rev. Drug. Discov.* **2002**, *1*, 198-210.
14. Michel, A.; Clay, W.; Ng, S.; Roman, S.; Thompson, K.; Condreay, J.; Hall, M.; Holbrook, J.; Livermore, D.; Senger, S. Identification of regions of the P2X₇ receptor that contribute to human and rat species differences in antagonist effects. *Br. J. Pharmacol.* **2008**, *155*, 738-751.
15. Michel, A.; Chambers, L.; Walter, D. Negative and positive allosteric modulators of the P2X₇ receptor. *Br. J. Pharmacol.* **2008**, *153*, 737-750.

16. Yoshimura, R. F.; Hogenkamp, D. J.; Li, W. Y.; Tran, M. B.; Belluzzi, J. D.; Whittemore, E. R.; Leslie, F. M.; Gee, K. W. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. *J. Pharmacol. Exp. Ther.* **2007**, *323*, 907-915.
17. Sancar, F.; Czajkowski, C. Allosteric modulators induce distinct movements at the GABA-binding site interface of the GABA-A receptor. *Neuropharmacology* **2011**, *60*, 520-528.
18. Trattnig, S. M.; Harpsøe, K.; Thygesen, S. B.; Rahr, L. M.; Ahring, P. K.; Balle, T.; Jensen, A. A. Discovery of a novel allosteric modulator of 5-HT₃ receptors-inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site. *J. Biol. Chem.* **2012**, *287*, 25241-25254.
19. Uebele, V.; Nuss, C.; Fox, S.; Garson, S.; Cristescu, R.; Doran, S.; Kraus, R.; Santarelli, V.; Li, Y.; Barrow, J.; Yang, Z.-Q.; Schlegel, K.-A.; Rittle, K.; Reger, T.; Bednar, R.; Lemaire, W.; Mullen, F.; Ballard, J.; Tang, C.; Dai, G.; McManus, O.; Koblan, K.; Renger, J. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. *Cell Biochem. Biophys.* **2009**, *55*, 81-93.
20. Chiu, P. J.; Marcoe, K. F.; Bounds, S. E.; Lin, C.; Feng, J.; Lin, A.; Cheng, F.; Crumb, W. J.; Mitchell, R. Validation of a [³H]astemizole binding assay in HEK293 cells expressing hERG K⁺ channels. *J. Pharmacol. Sci.* **2004**, *95*, 311-319.
21. Chadwick, C. C.; Ezrin, A. M.; O'Connor, B.; Volberg, W. A.; Smith, D. I.; Wedge, K. J.; Hill, R. J.; Briggs, G. M.; Pagani, E. D.; Silver, P. J. Identification of a specific radioligand for the cardiac rapidly activating delayed rectifier K⁺ channel. *Circ. Res.* **1993**, *72*, 707-714.
22. Finlayson, K.; Pennington, A. J.; Kelly, J. S. [³H]Dofetilide binding in SHSY5Y and HEK293 cells expressing a hERG-like K⁺ channel? *Eur. J. Pharmacol.* **2001**, *412*, 203-212.
23. Mitcheson, J. S. Drug binding to hERG channels: Evidence for a 'non-aromatic' binding site for fluvoxamine. *Br. J. Pharmacol.* **2003**, *139*, 883-884.
24. Perry, M.; Sachse, F. B.; Abbruzzese, J.; Sanguinetti, M. C. PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K⁺ conductance. *Proc. Natl. Acad. Sci. U S A* **2009**, *106*, 20075-20080.
25. Zhou, J.; Augelli-Szafran, C. E.; Bradley, J. A.; Chen, X.; Koci, B. J.; Volberg, W. A.; Sun, Z.; Cordes, J. S. Novel potent human ether-à-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. *Mol. Pharmacol.* **2005**, *68*, 876-884.
26. Shaguftha; Guo, D.; Klaasse, E.; de Vries, H.; Brussee, J.; Nalos, L.; Rook, M. B.; Vos, M. A.; van der Heyden, M. A.; IJzerman, A. P. Exploring chemical substructures essential for hERG K⁺ channel blockade by synthesis and biological evaluation of dofetilide analogues. *ChemMedChem* **2009**, *4*, 1722-1732.

27. Smith, P.; Krohn, R. I.; Hermanson, G.; Mallia, A.; Gartner, F.; Provenzano, M.; Fujimoto, E.; Goeke, N.; Olson, B.; Klenk, D. Measurement of protein using bicinchoninic acid. *Anal. Biochem.* **1985**, *150*, 76-85.
28. Diaz, G. J.; Daniell, K.; Leitz, S. T.; Martin, R. L.; Su, Z.; McDermott, J. S.; Cox, B. F.; Gintant, G. A. The [³H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K⁺]_o. *J. Pharmacol. Toxicol. Methods* **2004**, *50*, 187-199.
29. Heitman, L. H.; Oosterom, J.; Bongers, K. M.; Timmers, C. M.; Wiegerinck, P. H.; IJzerman, A. P. [³H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor. *Mol. Pharmacol.* **2008**, *73*, 518-524.
30. Almilaji, A.; Munoz, C.; Elvira, B.; Fajol, A.; Pakladok, T.; Honisch, S.; Shumilina, E.; Lang, F.; Föllner, M. AMP-activated protein kinase regulates hERG potassium channel. *Pflügers Arch. - Eur. J. Physiol.* **2013**, *465*, 1573-1582.
31. Heitman, L. H.; Ye, K.; Oosterom, J.; IJzerman, A. P. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. *Mol. Pharmacol.* **2008**, *73*, 1808-1815.
32. Kamiya, K.; Niwa, R.; Mitcheson, J. S.; Sanguinetti, M. C. Molecular determinants of hERG channel block. *Mol. Pharmacol.* **2006**, *69*, 1709-1716.
33. Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M. C. Physicochemical features of the hERG channel drug binding site. *J. Biol. Chem.* **2004**, *279*, 10120-10127.
34. Chen, F.; Larsen, M. B.; Neubauer, H. A.; Sánchez, C.; Plenge, P.; Wiborg, O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. *J. Neurochem.* **2005**, *92*, 21-28.
35. Duff, H. J.; Feng, Z.; Sheldon, R. S. High- and low-affinity sites for [³H]dofetilide binding to guinea pig myocytes. *Circ. Res.* **1995**, *77*, 718-725.
36. Zünkler, B.; Friemel, A. Allosteric interactions between terfenadine and chlorbutanol on hERG channels. *Toxicol. Lett.* **2009**, *189*, S257.
37. Perry, M.; Sanguinetti, M.; Mitcheson, J. Symposium review: Revealing the structural basis of action of hERG potassium channel activators and blockers. *J. Physiol.* **2010**, *588*, 3157-3167.
38. Vargas, H. M.; Bass, A. S.; Breidenbach, A.; Feldman, H. S.; Gintant, G. A.; Harmer, A. R.; Heath, B.; Hoffmann, P.; Lagrutta, A.; Leishman, D.; McMahon, N.; Mittelstadt, S.; Polonchuk, L.; Pugsley, M. K.; Salata, J. J.; Valentin, J.-P. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. *J. Pharmacol. Toxicol. Methods* **2008**, *58*, 72-76.
39. Liu, X.; Limberis, J. T.; Su, Z.; Houseman, K.; Diaz, G. J.; Gintant, G. A.; Cox, B. F.; Martin, R. L. Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers. *Life Sci.* **2012**, *90*, 607-611.

40. Wang, J.; Salata, J. J.; Bennett, P. B. Saxitoxin is a gating modifier of hERG K⁺ channels. *J. Gen. Physiol.* **2003**, *121*, 583-598.
41. Milnes, J. T.; Dempsey, C. E.; Ridley, J. M.; Crociani, O.; Arcangeli, A.; Hancox, J. C.; Witchel, H. J. Preferential closed channel blockade of hERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. *FEBS Lett.* **2003**, *547*, 20-26.
42. Reínés, A.; Zárate, S.; Peña, C.; de Lores Arnaiz, G. R. The effect of endogenous modulator endobain E on NMDA receptor is interfered by Zn²⁺ but is independent of modulation by spermidine. *Neurochem. Res.* **2004**, *29*, 819-825.
43. Elinder, F.; Århem, P. Metal ion effects on ion channel gating. *Q. Rev. Biophys.* **2003**, *36*, 373-427.
44. Milnes, J. T.; Crociani, O.; Arcangeli, A.; Hancox, J. C.; Witchel, H. J. Blockade of hERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. *Br. J. Pharmacol.* **2003**, *139*, 887-898.
45. Mitcheson, J. S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M. C. A structural basis for drug-induced long QT syndrome. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 12329-12333.
46. Lees-Miller, J. P.; Duan, Y.; Teng, G. Q.; Duff, H. J. Molecular determinant of high-affinity dofetilide binding to hERG1 expressed in xenopus oocytes: Involvement of S6 sites. *Mol. Pharmacol.* **2000**, *57*, 367-374.
47. Zhou, P.; Babcock, J.; Liu, L.; Li, M.; Gao, Z. Activation of human ether-à-go-go related gene (hERG) potassium channels by small molecules. *Acta Pharmacol. Sin.* **2011**, *32*, 781-788.
48. Duff, H. J.; Feng, Z.; Fiset, C.; Wang, L.; Lees-Miller, J.; Sheldon, R. S. [³H]Dofetilide binding to cardiac myocytes: Modulation by extracellular potassium. *J. Mol. Cell. Cardiol.* **1997**, *29*, 183-191.
49. Demo, S. D.; Yellen, G. Ion effects on gating of the Ca²⁺-activated K⁺ channel correlate with occupancy of the pore. *Biophys. J.* **1992**, *61*, 639-648.
50. Schetz, J. A.; Sibley, D. R. The binding-site crevice of the D₄ dopamine receptor is coupled to three distinct sites of allosteric modulation. *J. Pharmacol. Exp. Ther.* **2001**, *296*, 359-363.
51. Hogg, R. C.; Buisson, B.; Bertrand, D. Allosteric modulation of ligand-gated ion channels. *Biochem. Pharmacol.* **2005**, *70*, 1267-1276.

